Lisata Therapeutics Inc Stock Price, News & Analysis

Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on advanced solid tumor treatments, has announced its participation in three major industry events this November. The company will be present at BIO-Europe in Stockholm (Nov 4-6, with virtual sessions Nov 12-13), where VP Tariq Imam will conduct one-on-one meetings. At the PEGS Europe Summit in Barcelona (Nov 5-7), CEO David J. Mazzo will present on Nov 5 at 3:20 p.m. CEST. Additionally, Dr. Mazzo will present at the LSX Inv€$tival showcase in London's Tobacco Dock on Nov 18 at 1:00 p.m. GMT.

Lisata Therapeutics (Nasdaq: LSTA) has entered into a sponsored research agreement with the University of Cincinnati to study certepetide combined with bevacizumab for treating endometriosis. The research aims to leverage certepetide's selective targeting of endometrial tissue through surface integrin and neuropilin-1 receptors. While bevacizumab has shown efficacy in endometriosis treatment, its high dosage requirements cause systemic side effects. The partnership targets endometriosis, a condition affecting 6.5 million U.S. women, characterized by uterine tissue growth outside the uterus, causing pain and fertility issues.

Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has announced its participation in three upcoming industry and investor events in October 2024. These events include:

1. Pharma Partnering U.S. Summit (October 16-17) in Boston, MA, where Tariq Imam, VP of Business Development and Operations, will conduct one-on-one meetings.

2. BioFuture (October 28-30) in New York, NY, featuring a presentation by David J. Mazzo, PhD, President and CEO, on October 28 at 11:00 a.m. ET.

3. 17th Annual LD Micro Main Event (October 28-30) in Los Angeles, CA, where David J. Mazzo will present on October 29 at 11:00 a.m. PT.

These events offer opportunities for investors and industry professionals to learn more about Lisata's innovative therapies for advanced solid tumors and other serious diseases.

Lisata Therapeutics (Nasdaq: LSTA) has announced the treatment of the first patient in the second-line cholangiocarcinoma (CCA) cohort of the BOLSTER trial. This expansion follows the successful completion of enrollment in the first-line CCA cohort. The decision to initiate this cohort was based on recommendations from investigators in the first-line study. The BOLSTER trial is a Phase 2a, double-blind, placebo-controlled, randomized, multi-center study evaluating certepetide in combination with standard-of-care for first- or second-line CCA patients. This expansion aims to improve outcomes for patients who have progressed after first-line standard-of-care therapy alone.

Lisata Therapeutics (NASDAQ: LSTA), a clinical-stage pharmaceutical company, has announced its participation in two major industry events in September 2024. The company will be part of the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, with an on-demand virtual presentation available from September 9. Additionally, Lisata will present at the 2024 LSX World Congress USA on September 12 at 11:15 a.m. ET in Boston.

Dr. David J. Mazzo, President and CEO of Lisata, will be the presenter at both events. These conferences provide Lisata with opportunities to showcase its innovative therapies for advanced solid tumors and other serious diseases to investors and industry professionals.

Lisata Therapeutics (Nasdaq: LSTA) has received FDA Orphan Drug Designation for certepetide in treating cholangiocarcinoma, a rare and aggressive cancer. This designation is a significant step towards addressing the unmet need for new therapies in this area. Lisata is currently conducting the BOLSTER trial, a Phase 2a study evaluating certepetide for first- and second-line cholangiocarcinoma treatment. The trial is a double-blind, placebo-controlled, multi-center, randomized study taking place in the U.S. This development underscores Lisata's commitment to developing innovative therapies for advanced solid tumors and other serious diseases.

Lisata Therapeutics (LSTA) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. Phase 2b ASCEND trial top-line data for certepetide in metastatic pancreatic cancer expected in Q4 2024.

2. Available cash projected to fund operations into early 2026, covering all active studies.

3. Multiple ongoing Phase 2 trials for certepetide in various solid tumors.

4. Q2 2024 operating expenses decreased by 19.7% to $5.5 million compared to Q2 2023.

5. Net loss of $5.0 million for Q2 2024, compared to $4.0 million in Q2 2023.

6. Cash, cash equivalents, and marketable securities of $38.3 million as of June 30, 2024.

Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing innovative therapies for advanced solid tumors and other serious diseases, has announced its plans to report second quarter 2024 financial results on Monday, August 12, 2024, after market close. The company will host a conference call at 4:30 p.m. Eastern time to discuss the results and provide a business update.

Participants must pre-register for the conference call through a provided link. Registered participants will receive email instructions with dial-in options. To ensure a smooth experience, participants are encouraged to dial in 15 minutes before the scheduled start time. Additionally, a live webcast of the call will be available on Lisata's website under the Investors & News section, with a replay accessible for 12 months following the call.

Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics (Nasdaq: LSTA) have announced a research collaboration to evaluate the efficacy of a pancreatic cancer therapy. Lisata will use Haystack's MRD™ technology to detect circulating tumor DNA (ctDNA) in a clinical study of certepetide plus chemotherapy for metastatic pancreatic cancer.

The collaboration is part of the FORTIFIDE study, which investigates certepetide's safety, tolerability, and efficacy in combination with standard treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC). Haystack's technology will measure serum ctDNA levels throughout the study as an exploratory endpoint to analyze certepetide's early therapeutic effect.

This collaboration aims to address the challenge of early response measurement in pancreatic cancer treatment development, potentially offering a more sensitive alternative to conventional imaging assessments.